StreetAlpha.app
Home › Stocks › PACB

Pacific Biosciences of California, Inc. (PACB)

Healthcare
$1.82
▼ −1.09%
LAST CLOSE · NOV 17

Pacific Biosciences makes DNA sequencing systems, reagents and services for researchers, clinical labs and drug developers. It last closed at $1.82 on Nov 17, down 1.09% on the day. PACB reports earnings on Tue, Feb 9, 2027. The average 12-month price target from 3 analysts is $2.57 (+41.0% from the last close), with a high of $3.00 and a low of $2.00. Analyst consensus is Hold, based on the latest ratings from 3 firms (0 buy, 2 hold, 1 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in PACB, 33% of them bullish and 67% bearish. In the past 30 days there were 6 dark pool prints totaling $841K, the largest $169K.

AI Auto Pilots
Is PACB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$161.4M
+4.4% vs a year ago
Net income
−$131.2M
−81.3% margin
EPS (diluted)
−$0.42
Free cash flow
−$143.4M
−88.8% margin
Valuation
Market cap
$569.5M
312.9M shares
P/E
–
No P/E while losing money
Price to sales
3.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$55.9M
At Sep 30
Debt
$643.1M
At Sep 30
Shareholder equity
−$61.4M
Shares outstanding
312.9M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $130.5M$130.5MFY2021FY2022: $128.3M$128.3MFY2022FY2023: $200.5M$200.5MFY2023FY2024: $154.0M$154.0MFY2024FY2025: $160.0M$160.0MFY2025

From PACB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 9
2027 · Time not announced
Consensus EPS forecast
-$0.13
$47.5M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Hold
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
3firms
0 Buy2 Hold1 Sell
Each firm's latest rating on PACB in the past 90 days
Average 12-month target
$2.57
▲ 41.0% upside

Based on 3 analysts who set a price target on PACB in the past 90 days. The average target is $2.57, with a high of $3.00 and a low of $2.00, compared with the last close of $1.82.

$1$2$2$3PAST 14 TRADING DAYS12-MONTH TARGETSHIGH $3AVG $2.57LOW $2May 26LAST CLOSE+12 MO$1$2$2$3PAST 14 DAYSTARGETSHIGH $3AVG $2.57LOW $2May 26LAST CLOSE+12 MO
Highest target$3.00
Average target$2.57
Lowest target$2.00
Latest rating changes
UBSTarget raised
Nov 9Hold$1.35 → $2.70
BarclaysTarget raised
Nov 5Sell$1.50 → $2
Piper SandlerReiterated
Nov 5Hold$3
UBSAssumed coverage
Sep 9Hold$1.35
BarclaysDowngrade
Mar 6Sell$1.50
DateFirmActionRatingPrice target
Nov 9UBSTarget raisedHold$1.35 → $2.70
Nov 5BarclaysTarget raisedSell$1.50 → $2
Nov 5Piper SandlerReiteratedHold$3
Sep 9UBSAssumed coverageHold$1.35
Mar 6BarclaysDowngradeSell$1.50
Loading…

Technical Analysis

PACB · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 25% below its 20 day and 11% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 40). The nearest support is the Pivot at $1.81, and the nearest resistance the swing high (Jul 2) at $1.84.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 14.2%/day
Key levels
$3.4452 week high+89.0%
$2.2820 day average+25.3%
$2.0250 day average+11.0%
$1.89Pivot R1+3.8%
$1.84Swing high (Jul 2)+1.1%
$1.82Last close
$1.81Pivot−0.5%
$1.74Pivot S1−4.4%
$1.71100 day average−6.0%
$1.70Swing low (Oct 16)−6.6%
$1.60200 day average−12.1%
$1.0752 week low−41.2%
Indicators
RSI (14)39.82Weak, oversold below 30Neutral
MACD-0.04Below its signal lineBearish
Stochastic7.7Near the bottom of its rangeOversold
ADX (14)25.6Trending down
Williams %R-92.7Oversold below −80, overbought above −20Oversold
CCI (20)-129.9Oversold below −100, overbought above 100Oversold
Rate of change−25.4%Change over 10 sessionsBearish
ATR (14)$0.26Typical daily range, 14.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for PACB

What happened before

See how PACB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bearish1 bullish and 2 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow PACB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PACB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
3
Bullish
1
33%
Bearish
2
67%
Date span
Sep 30 – Oct 5
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
6
Notional
$841K
Largest print
$169K
Loading…

PACB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●90 buying vs 98 selling
  • ▲Held by funds +7.3 pts
  • ▼Funds holding -19
  • ▼Superinvestors: 2 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding204223−8.5%
In funds' top 10110.0%
Held by funds68.4%61.1%+7.3 pts
New / increased23 / 6723 / 70−3.2%
Reduced / sold out58 / 4077 / 29−7.5%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PACB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PACB is in one of them and how their past PACB trades turned out.

PACB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PACB in an article yet. Here's the latest on the wider market.

About Pacific Biosciences of California

Pacific Biosciences is a life science technology company based in Menlo Park, California, that designs and makes DNA sequencing systems. Its offerings include sequencing instruments, nanofluidic chips, reagents, software and sequencing services that read long stretches of DNA with high accuracy. Its customers include academic and government research institutions, clinical and testing laboratories, hospitals, public health labs, pharmaceutical companies, contract research organizations and agricultural companies.

Headquarters
Menlo Park, CA
Founded
2004